Last reviewed · How we verify
Ethyl methyl hydroxypyridine succinate + Meldonium
This combination product enhances cellular energy metabolism and reduces oxidative stress through antioxidant and cardioprotective mechanisms.
This combination product enhances cellular energy metabolism and reduces oxidative stress through antioxidant and cardioprotective mechanisms. Used for Acute myocardial infarction, Chronic heart failure, Cerebrovascular disease.
At a glance
| Generic name | Ethyl methyl hydroxypyridine succinate + Meldonium |
|---|---|
| Also known as | BRAINMAX® |
| Sponsor | Promomed, LLC |
| Drug class | Antioxidant/metabolic enhancer combination |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular, Neurology |
| Phase | FDA-approved |
Mechanism of action
Ethyl methyl hydroxypyridine succinate (Emoxypine succinate) is an antioxidant that scavenges free radicals and stabilizes cell membranes, while Meldonium enhances mitochondrial energy production by optimizing carnitine metabolism. Together, they improve cellular energy utilization and reduce ischemic damage, particularly in cardiac and cerebral tissues.
Approved indications
- Acute myocardial infarction
- Chronic heart failure
- Cerebrovascular disease
- Angina pectoris
Common side effects
- Gastrointestinal disturbances
- Dizziness
- Headache
- Allergic reactions
Key clinical trials
- Efficacy of the Therapy With BRAINMAX® Using fMRI for the Treatment of Patients With Asthenia After COVID-19 (PHASE4)
- Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After COVID-19 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: